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Abstract 
Background: Scleritis is a painful inflammatory process centered in the sclera that may involve the cornea and the 
underlying uvea. The etiology is commonly idiopathic or autoimmune but some cases are associated with systemic 
infection such as tuberculosis.
Case presentation: In this report, we describe an unusual case of a female Moroccan patient who had a long history 
of bilateral recurrent scleritis associated with peripheral keratopathy and anterior uveitis. The patient was diagnosed 
with latent tuberculosis and responded to antitubercular therapy administrated after exclusion of other aetiologies. 
This patient was finally diagnosed with latent tuberculosis- related scleritis.
Conclusions: Although systemic tuberculosis is reported as a possible cause of scleritis and other ocular inflamma-
tory manifestations, assessment of the diagnosis of tuberculosis-related ocular inflammation is challenging especially 
in latent forms. The treatment is largely presumptive. However, a favorable response to antitubercular therapy without 
relapse is taken as evidence of the disease.
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Background
Scleritis is typically a severe painful inflammatory pro-
cess centered in the sclera that may involve the adjacent 
tissues including the cornea and the underlying uvea [1]. 
It is a serious ocular condition that can lead to vision loss 
and therefore requires early diagnosis and treatment [2]. 
Scleritis is usually suspected from the clinical history, 
and confirmed by its characteristic clinical signs [1]. Fifty 
percent of patients with scleritis are diagnosed with an 
associated systemic disease including autoimmune con-
ditions and infections [2]. Tuberculosis-related scleritis 
is an uncommon ocular inflammatory disorder that pre-
sents challenges in diagnosis and management for both 
ophthalmologists and infectiologists [3]. This report 
describes a case of bilateral recurrent scleritis associated 
with peripheral keratopathy and anterior uveitis as ocular 
manifestations of latent tuberculosis.
Case presentation
A 43-year-old Moroccan female patient with a medical 
history of type 2 diabetes mellitus, presented with com-
plaints of pain, redness and blurring of vision of her left 
eye since 3 days. She had a previous history of multiple 
episodes of scleritis occurring in both eyes over the last 
5 years. During this time, the etiology of ocular inflam-
matory disorder remained unclear. Therapy consisted of 
oral non-steroidal anti-inflammatory drugs (NSAIDs) 
and topical steroids prescribed at every episode. Past 
ocular history also included a cataract surgery undergone 
on the left eye 2 years before. The patient, vaccinated at 
birth with BCG, reported a previous history of exposure 
to an active case of tuberculosis but denied any occurring 
feverish syndrome, night sweats, weight loss, shortness of 
breath or any other signs of systemic illness.
On examination, visual acuity was 5/10 right and 3/10 
left unaided. Both eyes, seen in natural light, had a dark 
coloration of the sclera typical of the scleromalacia. Slit 
lamp biomicroscopy of the left eye revealed dilatation 
of the deep episcleral vascular plexus and scleral edema 
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distinguished in a nodule adjacent to the temporal lim-
bus, measuring around 3 × 3 mm in size, firm, immobile, 
and tender to palpation (Fig.  1). The peripheral cor-
nea was seat of a crescent-shaped white-grayish opacity 
located 2 mm from the limbus with intact overlying epi-
thelium and thinned and infiltrated underlying stroma; 
which strongly suggested the presence of cicatrised 
peripheral ulcerative keratitis. There were also some foci 
of stomal infiltrates. The examination of the left eye also 
found a circumciliary congestion, + 2 cells and + 1 flare 
anterior chamber activity, an eccentric and irregular 
pupil, and a pseudophakic posterior chamber with opaci-
fication and phimosis of the anterior capsule. The exami-
nation of the right eye found similar corneal lesions, an 
optically empty anterior chamber, pigment deposits on 
the anterior lens capsule, and posterior subcapsular cata-
ract (Fig.  2). Intraocular pressure (Goldman tonometer) 
was 14 mmHg right and 10 mmHg left eye respectively. 
Fundoscopy was normal in both eyes, as well as fluores-
cein angiography and ultrasound B-scan. On the basis 
of these features, the patient was diagnosed with active 
nodular non necrotizing scleritis-associated with ante-
rior uveitis in the right eye and bilateral sequelae of pre-
vious episodes of sclerokeratitis and sclerouveitis.
The patient was hospitalized for etiologic inquiry. Sys-
temic examination including respiratory system was 
reported normal. Laboratory investigation found an ele-
vated erythrocyte sedimentation rate of 40  mm/h. The 
tuberculin skin test (TST) results showed a 20 mm indu-
ration and the QuantiFERON-TB Gold test was positive 
with value over 3 IU/ml. X-ray and CT scan of the chest 
revealed no specific pulmonary fibrotic lesions. Other 
investigations including routine haemogram, C-reactive 
protein, serum electrolytes, renal and hepatic functions, 
urine analysis, serum rheumatoid factor, antineutrophilic 
cytoplasmic antibodies (p and c), antinuclear antibod-
ies, angiotensin converting enzyme, syphilitic serology 
(TPHA-VDRL), serologies for viral hepatitis (B and C), 
ELISA for human immunodeficiency virus (1–2), sacro-
iliac joint radiographs and X-ray of sinus were normal. 
Biopsy of the sclera couldn’t be attempted due to the 
high risk of eye damage. Based on the foregoing clinical 
information and investigation results, the patient was 
diagnosed with presumptive latent tuberculosis-related 
scleritis. The inflammatory episode was well controlled a 
week after use of a selective cox-2 inhibitor and a topi-
cal corticosteroid. In addition, the patient received, under 
the supervision of the pneumologist, the first-line four-
drug anti-tubercular therapy including isoniazid 5  mg/
kg/day, rifampicin 10  mg/kg/day, ethambutol 15  mg/
kg/day, and pyrazinamide 25  mg/kg/day initially for 
2 months. Thereafter, isoniazid and rifampicin were used 
for an additional 7 months. Pyridoxine supplementation 
was given until cessation of therapy. No recurrences were 
observed over 12 months of follow-up since completing 
therapy.
Discussion
Scleritis is a severe inflammatory condition characterized 
by edema and cell infiltration of the sclera [4]. Accord-
ing to the classification of Watson and Hayreh, scleritis 
is divided into anterior and posterior types based upon 
the anatomic distribution of disease [5]. Anterior scle-
ritis, the most common type [1], is further subdivided 
into diffuse, nodular, necrotizing with inflammation, and 
necrotizing without inflammation (scleromalacia per-
forans) [5]. These forms of anterior scleritis correspond 
roughly to different degrees of severity [2].
Fig. 1 Cicatrised peripheral ulcerative keratitis, pigment deposits on 
the anterior lens capsule and posterior subcapsular cataract in the 
right eye
Fig. 2 Nodular scleritis and peripheral stromal keratitis in the left eye
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In eyes with scleritis, the inflammatory process may 
extend to adjacent structures, causing several complica-
tions that may lead to loss of vision [4]. Anterior scle-
ritis can be associated with anterior uveitis, cataracts, 
glaucoma and peripheral keratopathy [1, 2, 4, 6]. Clinical 
types of peripheral keratopathy associated with scleritis 
include peripheral corneal thinning (intact epithelium 
and no inflammatory cells in the stroma), stromal kera-
titis (intact epithelium but with inflammatory cells in 
the stroma and without stromal ulceration, and periph-
eral ulcerative keratitis (epithelial defect, inflammatory 
cells in the stroma, and stromal ulceration) [6]. Specific 
complications of posterior scleritis can include exudative 
retinal detachment, optic disk edema, cystoid macular 
edema, and choroidal folds [1, 2]. Other common com-
plications include scleral thinning and globe rupture with 
minor trauma [2].
Scleritis may be idiopathic or associated with local or 
systemic disease. Autoimmune conditions are found in 
approximately 40 % of patients and infections in approxi-
mately 7 % [2]. A large number of vasculitic and connec-
tive tissue diseases are associated with scleritis but the 
most common are rheumatoid arthritis and Wegener 
granulomatosis [1, 2]. Other less commonly associated 
systemic diseases include systemic lupus erythematosus, 
relapsing polychondritis, polyarteritis nodosa, inflam-
matory bowel disease, sarcoidosis, juvenile rheuma-
toid arthritis, ankylosing spondylitis, cryoglobulinemia, 
Cogan’s syndrome, systemic vasculitis, temporal and 
Takayasu arteritis [1, 2]. The most commonly associated 
infection is herpes zoster.
Tuberculosis (TB) is one possible infectious cause of 
scleritis and among other ocular inflammatory mani-
festations [7–12]. Ocular Mycobacterium tuberculosis 
(MTB) infection is most often a result of hematogenous 
dissemination from a distant site (such as lungs) [3, 9, 
12]. Infection may also occur by direct extension from 
surrounding tissue or direct inoculation [9, 12]. Defini-
tive diagnosis of ocular TB is based on demonstration of 
MTB in ocular samples, from polymerase chain reaction 
(PCR) detection, growth in cultures or detection of acid-
fast bacilli on smears [13, 14]. Such tests are not sensitive 
[3, 9] and even the caseating granulomatous inflamma-
tory lesion as histopathological evidence of ocular TB is 
rarely available [11, 14]. Ocular TB infection is difficult 
to diagnose due to the invasiveness of obtaining tissue 
samples, and limitations of available diagnostic tests [9]. 
Additionally, immune-mediated ocular TB can occur 
due to hypersensitivity to MTB antigens from a distant 
focus despite the absence of bacterium in the eye [3, 8, 
9, 11, 12]. Unfortunately, there is no pathognomonic 
clinical manifestation for ocular TB [9]. Considering 
this features, the diagnosis of ocular TB remain largely 
presumptive, supported by the combination of corrobo-
rative evidences such as suggestive history and clinical 
signs, detection of MTB in non-ocular samples or posi-
tive indirect tests for TB infection, radiologic findings of 
either active or latent TB infection, exclusion of other eti-
ologies and response to anti-tubercular treatment with-
out relapse [10, 12–14].
TB-related ocular inflammation mainly accompanies 
latent TB (LTB) [14], wherein the patient is infected with 
MTB but does not have active TB disease [9, 11, 14]. It 
is estimated that LTB affect one-third of the world’s pop-
ulation and about 10  % of patients with LTB will go on 
to develop active TB at a later stage of their life [9, 14]. 
Progression of LTB to active TB is more common among 
people with compromised immune systems and those 
with certain medical conditions [9] as diabetes present 
in our patient. In Morocco, country where TB is endemic 
with over 27,000 new cases detected annually, LTB as a 
possible etiology of scleritis and other ocular inflamma-
tions is often ignored. In the absence of others presumed 
etiologies, such manifestations continue to be labeled idi-
opathic and are often treated with topical corticosteroids 
and/or non-steroidal anti-inflammatory drugs. Systemic 
steroids and immunosuppressive drugs can also be used 
to manage the disease, and this may have catastrophic 
consequences in patients with undiagnosed LTB infec-
tion [3, 9, 11].
The methods currently available to detect LTB are the 
tuberculin skin test (TST) and the interferon gamma 
assays release assays (IGRAs) [9, 11]. The TST is the 
oldest and most widespread test used for tuberculo-
sis diagnosis [9]. Its drawbacks are operator-dependent 
placement and reading. Sometimes, a history of BCG 
vaccination can yield false-positive results due to a cross-
reaction with Bacillus Calmette-Guérin (BCG) that 
contains a strain of the closely related bacteria, Mycobac-
terium bovis, but in our case, given the interval between 
the vaccination and the TST, it seems unlikely [9, 15]. 
IGRAs, such as QuantiFERON-TB Gold, are in  vitro 
tests that measures IFN-γ released when whole blood is 
stimulated with 2 synthetic peptides, the early secreted 
antigenic target 6-kDa protein (ESAT-6) and the 10-kDa 
culture filtrate protein (CFP-10), both found in MTB but 
not in the BCG vaccine or in the vast majority of atypi-
cal mycobacterium [15]. However, the QuantiFERON-TB 
gold is expensive and most patients in developing coun-
tries cannot afford it. Thus, QuantiFERON-TB Gold is 
more specific for LTB infection than the tuberculin skin 
test in a population recently vaccinated by BCG, but the 
TST gives a better cost-effectiveness pattern [14–16]. In 
the present case, the TST result was positive with indura-
tion large enough to raise our suspicion of TB. The QFT 
testing strengthened the diagnosis.
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Ocular TB is treated with medical anti-tuberculosis 
treatment (ATT) similar to that for pulmonary TB [13]. 
The CDC recommends the use of all four drugs (isonia-
zid, rifampicin, pyrazinamide, and ethambutol) for an 
initial 2-month period followed by a choice of different 
options over the next 4–7  months. A low dose steroid 
given concomitantly with anti-tubercular therapy drugs 
for 4–6 weeks has been shown to have a protective effect 
against tissue damage from delayed hypersensitivity [7, 
10, 13, 14]. In patients with LTB-related ocular inflam-
mation, the administration of ATT would lead to reduce 
ocular inflammation and its futures recurrences as the 
inciting MTB load is reduced [13]. All of these decisions 
should be made in collaboration with an infectious dis-
ease specialist.
Conclusions
Tuberculosis, including latent form, is a possible infec-
tious cause of scleritis and other ocular inflammatory 
manifestations. Delayed diagnosis can lead to vision loss 
and systemic complications of the infection. Tubercu-
losis-related ocular inflammation is a challenging clini-
cal entity that may be difficult to diagnose and manage. 
However, a favorable response to ATT without relapse is 
taken as evidence of the disease.
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